MINX launches Monday. It’s our 5 mg oral minoxidil lipid-matrix capsule, with in vitro dissolution data showing slower release versus an immediate-release comparator. Same active ingredient, designed for a more gradual release profile. Not VDPHL01, not FDA-approved extended release, and not clinical proof, but a more thoughtful approach to oral minoxidil.
Oral minoxidil is one of the most talked-about treatments in hair loss right now. The reason is simple: topical minoxidil works for many people, but it can be frustrating to use. It can be messy, irritating, difficult to apply consistently, and inconvenient as part of a long-term routine.
Oral minoxidil solves some of those problems. One pill is easier than applying a topical treatment every day. But standard oral minoxidil has a different issue: it releases very quickly.
That is why we built MINX.
MINX is our lipid-matrix oral minoxidil formulation. It contains the same active ingredient, minoxidil, but is designed to release more gradually instead of all at once. The goal is not to reinvent minoxidil. The goal is to make the oral minoxidil experience more thoughtfully designed, with the same drug and a smoother release curve.
To be clear, this is a hypothesis that has not been fully validated: Most oral minoxidil tablets available today are immediate-release tablets. They were not originally designed for hair loss. They were developed as blood pressure medication, which means they release minoxidil quickly after swallowing.
For hair growth, that release pattern may matter. Oral minoxidil is not just about how much minoxidil you take. It is also about how much your body can tolerate, how long the drug is available, and how efficiently minoxidil can be converted into minoxidil sulfate, the active form involved in hair growth.
The theory behind a more gradual release profile is that it may change the tradeoff. If minoxidil is released all at once, the body gets a sharper early exposure. That may limit how much some patients can tolerate. If minoxidil is released more gradually over many hours, it could, in theory, allow for a smoother exposure window and make higher effective dosing more tolerable for some people.
That matters because higher doses of oral minoxidil may drive more hair growth, but tolerability is often the limiting factor. It also matters because minoxidil needs to be converted into minoxidil sulfate to exert its hair growth effects. A more gradual release profile could, in theory, give the body a longer window to convert minoxidil into its active form rather than delivering the dose all at once.
We recently tested MINX against a standard oral minoxidil tablet in lab dissolution testing. The difference was clear.
In our testing, standard oral minoxidil released almost the full dose in under 10 minutes. MINX released much more gradually, over approximately 12 to 14 hours.
We tested this in two different environments. One was pH 1.2, an acidic environment meant to mimic the stomach. The other was pH 6.8, which is meant to mimic the small intestine.
That matters because after you swallow a pill, it starts in the stomach and then moves into the small intestine. In both conditions, the key point was the same: standard oral minoxidil released very quickly, while MINX released much more slowly.
We want to be very clear about what this means. This is dissolution data. It shows how the tablet and capsules releases in lab conditions.
It is not the same thing as human clinical data. It does not prove better hair growth. It does not prove fewer side effects. And MINX is not an FDA-approved extended-release oral minoxidil product.
But it does show something important: MINX behaves very differently from a standard immediate-release minoxidil tablet in vitro. That is exactly what we set out to build.
Recently, there has been a lot of attention on Veradermics’ VDPHL01, an investigational extended-release oral minoxidil product being studied for hair loss.
To be clear, MINX is not VDPHL01. It is not Veradermics’ drug. It is not the same formulation. And it does not have Veradermics’ clinical data.
But MINX was built around the same basic idea: can we make oral minoxidil release more gradually instead of all at once? That is what MINX is designed to do.
MINX launches Monday, and the waitlist is live now for people who want early access when the product becomes available.
Oral minoxidil is still a medication. It is not right for everyone, and you should talk to a doctor before starting, especially if you have a history of cardiovascular issues, blood pressure concerns, dizziness, swelling, or fluid retention.
MINX is not about pretending oral minoxidil is risk-free. It is about asking whether oral minoxidil can be designed more thoughtfully.
Sign up here if you're interested: MINX Waitlist
MINX launches Monday. It’s our 5 mg oral minoxidil lipid-matrix capsule, with in vitro dissolution data showing slower release versus an immediate-release comparator. Same active ingredient, designed for a more gradual release profile. Not VDPHL01, not FDA-approved extended release, and not clinical proof, but a more thoughtful approach to oral minoxidil.
Oral minoxidil is one of the most talked-about treatments in hair loss right now. The reason is simple: topical minoxidil works for many people, but it can be frustrating to use. It can be messy, irritating, difficult to apply consistently, and inconvenient as part of a long-term routine.
Oral minoxidil solves some of those problems. One pill is easier than applying a topical treatment every day. But standard oral minoxidil has a different issue: it releases very quickly.
That is why we built MINX.
MINX is our lipid-matrix oral minoxidil formulation. It contains the same active ingredient, minoxidil, but is designed to release more gradually instead of all at once. The goal is not to reinvent minoxidil. The goal is to make the oral minoxidil experience more thoughtfully designed, with the same drug and a smoother release curve.
To be clear, this is a hypothesis that has not been fully validated: Most oral minoxidil tablets available today are immediate-release tablets. They were not originally designed for hair loss. They were developed as blood pressure medication, which means they release minoxidil quickly after swallowing.
For hair growth, that release pattern may matter. Oral minoxidil is not just about how much minoxidil you take. It is also about how much your body can tolerate, how long the drug is available, and how efficiently minoxidil can be converted into minoxidil sulfate, the active form involved in hair growth.
The theory behind a more gradual release profile is that it may change the tradeoff. If minoxidil is released all at once, the body gets a sharper early exposure. That may limit how much some patients can tolerate. If minoxidil is released more gradually over many hours, it could, in theory, allow for a smoother exposure window and make higher effective dosing more tolerable for some people.
That matters because higher doses of oral minoxidil may drive more hair growth, but tolerability is often the limiting factor. It also matters because minoxidil needs to be converted into minoxidil sulfate to exert its hair growth effects. A more gradual release profile could, in theory, give the body a longer window to convert minoxidil into its active form rather than delivering the dose all at once.
We recently tested MINX against a standard oral minoxidil tablet in lab dissolution testing. The difference was clear.
In our testing, standard oral minoxidil released almost the full dose in under 10 minutes. MINX released much more gradually, over approximately 12 to 14 hours.
We tested this in two different environments. One was pH 1.2, an acidic environment meant to mimic the stomach. The other was pH 6.8, which is meant to mimic the small intestine.
That matters because after you swallow a pill, it starts in the stomach and then moves into the small intestine. In both conditions, the key point was the same: standard oral minoxidil released very quickly, while MINX released much more slowly.
We want to be very clear about what this means. This is dissolution data. It shows how the tablet and capsules releases in lab conditions.
It is not the same thing as human clinical data. It does not prove better hair growth. It does not prove fewer side effects. And MINX is not an FDA-approved extended-release oral minoxidil product.
But it does show something important: MINX behaves very differently from a standard immediate-release minoxidil tablet in vitro. That is exactly what we set out to build.
Recently, there has been a lot of attention on Veradermics’ VDPHL01, an investigational extended-release oral minoxidil product being studied for hair loss.
To be clear, MINX is not VDPHL01. It is not Veradermics’ drug. It is not the same formulation. And it does not have Veradermics’ clinical data.
But MINX was built around the same basic idea: can we make oral minoxidil release more gradually instead of all at once? That is what MINX is designed to do.
MINX launches Monday, and the waitlist is live now for people who want early access when the product becomes available.
Oral minoxidil is still a medication. It is not right for everyone, and you should talk to a doctor before starting, especially if you have a history of cardiovascular issues, blood pressure concerns, dizziness, swelling, or fluid retention.
MINX is not about pretending oral minoxidil is risk-free. It is about asking whether oral minoxidil can be designed more thoughtfully.
Sign up here if you're interested: MINX Waitlist
